Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2007 April;98(2) > Minerva Medica 2007 April;98(2):121-30



A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2007 April;98(2):121-30



Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines

Hampl M.

Department of Gynecology and Obstetrics Heinrich Heine University Düsseldorf, Germany

Persistent infection with human papilloma virus (HPV) is a necessary condition for the development of cervical, most of the vulvar and anal carcinoma and their precursors. HPV is the most common sexually transmitted virus throughout the world. About 70-80% of sexually active people are infected during their lifetime. Most infections are transient and asymptomatic and cleared by the host immune system within 12-18 months. Only persistent infections predispose to the development of genital preneoplasia and cancer. The first vaccine against HPV infection has been available in Italy since March 2006. The vaccine is a prophylactic, quadrivalent vaccine against the two most common oncogenic HPV types 16 and 18, responsible for more than 70% of cervical carcinomas and against the two low-risk types 6 and 11 responsible for 90% of cases of genital warts. A second, bivalent HPV 16/18 vaccine will be launched soon. The immunogenicity (100%) and efficacy of the vaccines is very high (96% against infection, 100% against disease). These vaccines constitute a milestone in the battle against cervical carcinoma, which is the second most common cancer in young women in Europe, with 33 500 new cases diagnosed every year.
Key words: Vaccines - Prophylaxis - Neoplasms - Papillomavirus vaccines.
Molecular biological mechanisms of infection with human papilloma viruses

language: English


top of page